Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Triple negative breast cancer control through synergistic inhibition of EGFR and CDK9 signaling (TRIPLECON)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Netherlands,Netherlands
Call: ERC-Proof of Concept (ERC-2017-PoC, 2017)
Start date: 2017-10-01
End date: 2018-09-30
Duration (months): 12.0
Total project cost (EUR): 150000.0
EU funding (EUR): 90075.0
Participants: 2
Project status: CLOSED

Triple negative breast cancer (TNBC) is an aggressive disease, accounting for 15-20% of breast cancer cases, but disproportionally causing breast cancer-related death. TNBC does not express the targetable receptors ER, PR, and HER2 that are known to drive other forms of breast cancer. Mainstay practice for TNBC in the clinic is to treat with non-targeted cytotoxic chemotherapies. Long-term outcomes are however still poor, most likely owing to intrinsic drug resistance. Clinical trials have attempted to explore molecular targeted therapies to block dysregulated growth factor receptors in TNBC, for instance, epidermal growth factor receptor (EGFR), as it is overexpressed in ~80% of TNBC. Yet, giving the long-standing availability of clinically approved EGFR-targeted therapies, such as lapatinib, the clinical benefit of single agent therapy is unsatisfactory, owing to the compensatory dysregulated signaling pathways. In our ongoing ERC – Advanced Grant Triple-BC (#322737) we are striving to explore combinatorial molecular targeted therapies to concomitantly block the identified dysregulated signaling pathways. Our preliminary work revealed that an inhibitor targeting cyclin-dependent kinase 9 (CDK9) strikingly synergized with targeting EGFR receptor family signaling to inhibit cell proliferation of TNBC cell lines. The overall goal of this PoC project is to exploit this novel finding and provide proof-of-concept evidence that stalling CDK9 signaling may enable successful targeted combination therapy in TNBC. Therefore, the specific objective is to assess the pharmacological response of dual EGFR-CDK9 targeting in TNBC patient-derived xenograft (PDX) mouse models in vivo. We envisage that this PoC project will translate our identified successful synergistic treatment into an effective future novel and safe combinatorial targeting strategy benefiting TNBC patients.

Keywords: triple negative breast cancer drug resistance synthetic lethality patient derived xenografts pdx dual egfr and cdk9 inhibition combinational targeted therapy
CUTTING-EDGE ENVIRONMENTALLY FRIENDLY TECHNOLOGY ENABLING THE PRODUCTION OF EXTREMELY DURABLE PLASTIC COMPOSITES, REINFORCED BY BASALT FIBRE (COBAS)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Germany
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-06-01
End date: 2018-11-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Our company, AFEX GmbH, (http://www.afex-kunststoff.de) was established in 1998 as a innovative daughter company of the technical centre of A-FORM AG (leading manufacturer of moulds and developer of technologies for plastic forming, see video presentation: http://media.kabeljournal.de/www.a-form.de/a-form.mp4). AFEX is a leading German manufacturer of high-grade components from various plastic materials (PA, ABS, PC, PPS, PPV, PEEK) for the professional automotive (VW, BMW, Audi, Bentley and others), medical, consumer goods industries with a headcount of 22 persons and an annual revenue of 2.66 million €. Our goal is to recognize industry needs and develop performance-rich innovative products of the highest quality. Our products are available in more than 27 countries in Europe, America, India and Asia through our marketing and sales department and global network of customers and partners. We also find it important to present our latest technologies and products at the finest exhibitions and conventions worldwide. For 19 years our company has been involved in the manufacturing of complex plastic components using highly diverse materials. In 2013-2017 we developed - from a national fund and our own resource - an advanced plastic material based on basalt fiber fillers (uncoated) allowing significant improvement of plastic products properties and also demonstrated this material and fabrication method for some customers from automotive industry as well as further industries. With the help of the SME instrument funding we wish to further develop our high-potential innovative technology allowing the series production of these highly innovative polyamide (PA) plastic parts reinforced with chopped basalt (PABF) fibers and widely sell them to automotive industry. If the feasibility assessment will have positive result we will continue the project. The EC investment will have its return in 2-3 years after the market entry.

Keywords: basalt fibre,recycled,highly innovative polymide plastic parts
PLUG AND PLAY intelligent transport system for bus and coach sector (MUGICLOUD)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: SME instrument
Countries involved: Spain
Call: Small business innovation research for Transport and Smart Cities Mobility (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-08-01
End date: 2018-01-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

During the last decades, the volume of road transport has increased in the European Union associated with the growth of the European economy and mobility requirements of citizens. In fact, between 2010 and 2015, road freight transport increased by 8,1 % (measured in tonne-kilometres) and road passenger transport around 3,5%(measured in passengers per kilometre - pkm) . This growth has lead into an increasing congestion of road infrastructure and rising energy consumption, which means economic, environmental and social problems. Bus and coach are the direct alternative to the car, as their infrastructure allows greater accessibility than other collective ways of transport (such as train or plane) and it offers safety and environmental advantages over other ways of transport. However, in a context in which passenger transport (in terms of pkm) has grown more than 20% between 1995 and 2015, the use of bus and coach has only increased by 4,5% during this period. The reason behind these figures lays on how each way of transport has improved the quality of their service for passengers. Therefore, it is necessary to improve the satisfaction of bus and coach passengers to attract them to this way of transport and thus achieve greater sustainable mobility. In this context, the company Wirelesscities Networks (WNetworks) has developed, in constant contact with bus & coach SME operators, a new product, mugiCloud. mugiCloud is an Intelligent Transport System (ITS), a Plug&Play product which integrates telecommunications, electronics and information technologies with transport engineering in order to plan, design, operate, maintain and manage transport systems. The system captures data and, through software and new apps already developed by WNetworks, translates these data into information for passengers, drivers and fleet managers.

Keywords: transport,coach,fleet manager,plugandplay
Buildings as Material Banks: Integrating Materials Passports with Reversible Building Design to Optimise Circular Industrial Value Chains (BAMB)

Framework: Horizon 2020 — Societal Challenges
Programme: Climate action, environment,  resource efficiency and raw materials
Theme: Enabling the transition towards a green economy and society through eco-innovation
Action type: Innovation actions
Countries involved: Germany,Germany,Germany,Belgium,Bulgaria,Sweden,Sweden,Bosnia and Herzegovina,Belgium,Sweden,Netherlands,Netherlands,Netherlands,Netherlands,Portugal,United Kingdom
Call: Moving towards a circular economy through industrial symbiosis (H2020-WASTE-2014-two-stage, 2014)
Start date: 2015-09-01
End date: 2019-02-28
Duration (months): 42.0
Total project cost (EUR): 9918629.77
EU funding (EUR): 8858763.02
Participants: 22
Project status: CLOSED

The aims of BAMB (Buildings as Material Banks) are the prevention of construction and demolition waste, the reduction of virgin resource consumption and the development towards a circular economy through industrial symbiosis, addressing the challenges mentioned in the Work Programme on Climate action, environment, resource efficiency and raw materials. The focus of the project is on building construction and process industries (from architects to raw material suppliers). The BAMB-project implements the principles of the waste hierarchy: the prevention of waste, its reuse and recycling. Key is to improve the value of materials used in buildings for recovery. This is achieved by developing and integrating two complementary value adding frameworks, (1) materials passports and (2) reversible building design. These frameworks will be able to change conventional (cradle-to-grave) building design, so that buildings can be transformed to new functions (extending their life span) or disassembled to building components or material feedstock that can be upcycled in new constructions (using materials passports). This way, continuous loops of materials are created while large amounts of waste will be prevented. Activities from research to market introduction are planned. Fundamental knowledge gaps should be bridged in order to introduce both frameworks on the market. Advanced ICT tools and management models will enable market uptake and the organization of circular value chains in building and process industries. New business models for (circular) value chains will be developed and tested on selected materials. The inclusion of strategic partners along the value chains in an industrial board will maximize market replicability potential, while several (mostly privately funded) building pilots will demonstrate the potential of the new techniques. Awareness will be raised to facilitate the transition towards circularity by policy reform and changing consumer behavior.

Keywords: materials passports,reversible building design,industrial symbiosis,construction and demolition waste,upcycling materials,continuous loops of materials
Ultra High Efficiency Radiation Hard Space Solar Cells on Large Area Substrates (RadHard)

Framework: Horizon 2020 — Industrial Leadership
Programme: Space
Theme: Enabling European competitiveness, non-dependence and innovation of the European space sector
Action type: Research and Innovation actions
Countries involved: Austria,Germany,Germany,Germany,Germany,Belgium,Belgium,France,France
Call: Technologies for European non-dependence and competitiveness (H2020-COMPET-2017, 2017)
Start date: 2018-01-01
End date: 2022-01-31
Duration (months): 49.0
Total project cost (EUR): 3072972.5
EU funding (EUR): 3072972.5
Participants: 9
Project status: CLOSED

Project RadHard aims for increasing both the technical and commercial competitiveness of the European space solar cell technology to maintain the independence of European space industry in this field. RadHard will demonstrate the future next generation of space solar cells featuring i) beginning-of-life efficiency exceeding 35% under AM0 condition enabled by a new, patent protected 4-junction space solar cell, ii) the world’s highest radiation hardness leading to an efficiency >31% after 1E15 cm-2 1MeV electron irradiation, iii) scaling of the solar cell manufacturing to 200mm wafer size to enable competitive cost of the product and iv) demonstration of manufacturability and reliability of this cell concept. TR levels for relevant technologies will be increased from TRL 3 to 5-6. The project makes use of technology innovations in solar cells design, epitaxy, semiconductor bonding and ultra large Ge wafers. The work plan is based on a parallel development of the new solar cell by semiconductor bonding and establishing solar cell manufacturing processes on 200 mm Ge wafers. At the end of the project, these development lines will be merged to demonstrate the commercial viability of the selected approach. Technology development activities will be accompanied by extensive test programme to allow for continuous feedback on the achieved device performance and to address reliability aspects. Finally an industrialization plan for the new 4-junction semiconductor bonded solar cell will be elaborated. The project team is led by AZUR SPACE and consists of 7 industrial partners (incl. 1 SME) and 2 academic institutes and covers all R&D aspects, from basic research on advanced materials at academic partners to device manufacturing in industrial environment and testing on higher integration level. The relevance of the team for commercial exploitation is extremely high: RadHard includes industrial partners from each of the main parts of the value chain for space solar generators.

Keywords: high efficiency radiation hard four junction solar cells,semiconductor bonding technology,bol efficiency above 35,eol efficiency above 31,ultra large 200 mm ge wafers
Technology for 2G biofuel and biosolvents production verified in a pilot plant (BIO2G)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Slovakia,Slovakia,Slovakia,Czechia,Luxembourg
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2019-02-01
End date: 2019-07-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 5
Project status: CLOSED

The project shall provide unique BIO2G biorefinery technology for production of the 2nd generation environmental-friendly biofuel (biobutanol) and biosolvents (bioacetone, bioethanol) from lignocellulose raw materials. The technology is innovative combination of two existing technologies, where the first is pre-treatment of biomass with follow-up production of sugars and second one is ABE technology, for production of biobutanol, bioacetone and bioethanol, where raw materials are C5 and C6 sugars. The BIO2G process is the result of research of the Consortium and verified on a laboratory prototype, addresses the following problems of the biofuel market: (a) Reduction of GHG emission from transport fuels by (b) Substitution of food or feed origin raw materials for biofuels production, by non-food raw materials, thus, fulfilling of future EU legislation criteria set for production and usage of 2nd generation biofuels. Economic and societal impact: (a) creates a new form of agricultural and forest residuals utilization for industrial production (b) opportunity for utilizing polluted and low-grated soil for the cultivation of energy plants used for BIO2G technology. These new opportunities enable the utilization of non-food raw materials for BIO2G and shall create a new era of rural development with new farm job opportunities. The three key inter-related objectives and deliverables of the project: I. Detailed development of the proposed BIO2G technology for biofuels and biosolvents production updated by the verification result. II. Practical verification of the feasibility and sustainability the BIO2G technology in a pilot plant in different processing scenarios (by raw material type, process parameters, cost of operations). III. Transfer of know-how and technical assistance for multiple deployment of BIO2G in other regions of the EU. Formation of BIO2G international research and business partner network.

Keywords: biobutanol,biosolvents,biomass c5 sugars,c6 sugars
Viruses, Immune stimulation and RNA Interference in Oncology Network (VIRION)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Industrial Doctorates
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Finland,Netherlands,Netherlands,Netherlands,United Kingdom
Call: Marie Skłodowska-Curie Innovative Training Networks (ITN-EID) (H2020-MSCA-ITN-2014, 2014)
Start date: 2015-10-01
End date: 2019-09-30
Duration (months): 48.0
Total project cost (EUR): 1304413.56
EU funding (EUR): 1304413.56
Participants: 9
Project status: CLOSED

The Viruses, Immune stimulation and RNA Interference in Oncology Network (VIRION) is focused on the execution of an internationally competitive cancer research project focused on the development of a novel therapeutic regime by combining immune therapy with oncolytic virotherapy and RNA interference techniques. Recent clinical successes have shown the immune system to be a powerful ally in the fight against cancer. While surgery, chemotherapy and radiation therapy remain the first lines of treatment for most tumors, immunotherapy regimens have had astonishing clinical successes. Furthermore, recent studies have shown that pre-existing lymphocytic infiltration of tumors is associated with superior prognostic outcomes in a variety of cancers and might improve cancer therapies targeting immune checkpoints. A recent development in the immunotherapy field is adoptive cell therapy (ACT). In ACT lymphocytes from cancer patients are expanded ex vivo into more favorable numbers, they can be modified genetically or stimulated to relieve immune suppression and infused back into the patient. In clinical trials, ACT has resulted in anti tumor responses. However, immune suppression in the tumor microenvironment limits the efficacy of immunotherapy and remains a major hurdle. We aim to potentiate the antitumor immune reaction in the tumor microenvironment through the combination of immune therapy and oncolytic virotherapy. Oncolytic viruses are developed to specifically target and destroy tumor cells. In pre-clinical models, oncolytic adenoviruses have proven a powerful tool in the elimination of tumors, not only by their direct lytic effects but also by their triggering of a subsequent tumor inflammation and enhanced lymphocytic infiltration. VIRION will address how these immune responses can be further enhanced by addition of immune modulating factors and/or siRNA targeting tumor genes that play an immune suppressive role in the tumor micro environment.

Keywords: immune therapy,adaptive cell therapy,tumor infiltrating lymphocytes,anti tumour immune response,oncolytic virotherapy,rna interference
Intestinal Lipoidal Nanostructures - A Lipid Bridge to Increased Drug Delivery (INTESTINANOS)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: Sweden
Call: ERC Starting Grant (ERC-2014-STG, 2014)
Start date: 2015-09-01
End date: 2020-08-31
Duration (months): 60.0
Total project cost (EUR): 1706250.0
EU funding (EUR): 1706250.0
Participants: 1
Project status: CLOSED

My research program explores molecular interplay between drug, dosage form and the complex environment of the gastrointestinal tract (GIT). Drug molecules currently being discovered to cure e.g. CNS diseases, cancer and the metabolic syndrome show poor water solubility and 70-90% of recently discovered drugs have too poor solubility to allow absorption from the GIT. For such compounds the dosage form can significantly improve the absorption. My long-term goal is to establish a computational platform that predicts, from molecular structures and computational tools, the development potential of drug molecules to well-functioning orally administered medicines. A major gap to understand drug performance in the intestine is the poor knowledge of the dynamics of solubilizing lipoidal nanostructures (micelles, vesicles, oil droplets) present in the fluid. This project explores restructuring of these lipid colloids in response to intake of food or dosage forms, enzymatic digestion, absorption and transit along the GIT. Novel experimental tools are developed to reveal the impact of these nanostructures on drug solubilization, supersaturation and likelihood of precipitation in vivo, all being important for drug absorption. The experimental results are fed into in silico models taking use of Molecular Dynamics simulations to develop a computational platform predicting drug performance in the dynamic intestinal milieu. The novel tools designed herein will allow dosage forms that improve performance and increase drug absorption after oral administration to, for the first time, be designed by computational means. The results of this project, in particular the novel in silico tools exploring rearrangement of lipoidal nanostructures, are highly important to related areas such as GIT disease models and food processing but also have wider applications in e.g. studies of intracellular vesicle rearrangements and transport processes in plants.

Keywords: poorly soluble drugs,dissolution,intestinal fluid,lipolysis,colloidal rearrangement,lipid based drug delivery,molecular dynamics simulations,computational pharmaceutics
Leveraging AI based technology to transform the future of health care delivery in Leading Hospitals in Europe (ODIN)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Innovation actions
Countries involved: Germany,Spain,Italy,Italy,Italy,Austria,Spain,Italy,Poland,Switzerland,Greece,Greece,Greece,France,France,Netherlands,Netherlands,United Kingdom
Call: AI for the smart hospital of the future (H2020-DT-2020-1, 2020)
Start date: 2021-03-01
End date: 2024-08-31
Duration (months): 42.0
Total project cost (EUR): 11375651.38
EU funding (EUR): 9948545.0
Participants: 22
Project status: SIGNED

Hospitals must increase their efficiency and productivity and boost quality and safety, while containing and reducing costs. This cannot be an untaught linear reduction. For instance, the number of ICU beds per million of EU habitants was reduced of 75% in the past 30 years, also in response to the unneglectable need to invest on territory healthcare services in response to democratic challenges. This left EU Hospitals completely unprepared to the COVID-19 pandemics, proving that hospital budget cuts must be complemented with major organizational restructuring, making use of innovative technologies. We have identified 11 hospital critical challenges, which ODIN will face combining robotics, Internet of Things (IoT) and Artificial Intelligence (AI) to empower workers, medical locations, logistics and interaction with the territory. ODIN will deploy technologies along three lines of intervention: empowering workers (AI, cybernetics and bionics), introducing autonomous and collaborative robots and enhancing medical locations with IoT. These areas of intervention will be piloted in six hospitals (in Spain, France, Italy, Poland, The Netherland, Germany), via seven use cases, spanning from clinical to logistic, including patient management, disaster preparedness and hospital resiliency.ODIN pilot will be a federation of multicentre longitudinal cohort studies, demonstrating the safety, effectiveness and cost-effectiveness of ODIN technologies for the enhancement of hospital safety, productivity and quality. Use-case protocols will be approved by the local hospital ethical committees, in order to assure the highest quality of the study, while providing a pragmatic solution for the scaling-up of the ODIN technological solutions and business models in a variety of local ecosystems. ODIN vision is that as Evidence Based Medicine revolutionized medicine with data-driven procedures, so data-driven management (enabled by Industry 4.0 tech) can revolutionise hospital management

Keywords: hospital of future,efficiency gain,european wide impact dimension,sustainable innovation